| First Author | Oka S | Year | 2016 |
| Journal | Sci Rep | Volume | 6 |
| Pages | 37889 | PubMed ID | 27897204 |
| Mgi Jnum | J:287498 | Mgi Id | MGI:6407614 |
| Doi | 10.1038/srep37889 | Citation | Oka S, et al. (2016) Human mitochondrial transcriptional factor A breaks the mitochondria-mediated vicious cycle in Alzheimer's disease. Sci Rep 6:37889 |
| abstractText | In the mitochondria-mediated vicious cycle of Alzheimer's disease (AD), intracellular amyloid beta (Abeta) induces mitochondrial dysfunction and reactive oxygen species, which further accelerate Abeta accumulation. This vicious cycle is thought to play a pivotal role in the development of AD, although the molecular mechanism remains unclear. Here, we examined the effects of human mitochondrial transcriptional factor A (hTFAM) on the pathology of a mouse model of AD (3xTg-AD), because TFAM is known to protect mitochondria from oxidative stress through maintenance of mitochondrial DNA (mtDNA). Expression of hTFAM significantly improved cognitive function, reducing accumulation of both 8-oxoguanine, an oxidized form of guanine, in mtDNA and intracellular Abeta in 3xTg-AD mice and increasing expression of transthyretin, known to inhibit Abeta aggregation. Next, we found that AD model neurons derived from human induced pluripotent stem cells carrying a mutant PSEN1(P117L) gene, exhibited mitochondrial dysfunction, accumulation of 8-oxoguanine and single-strand breaks in mtDNA, and impaired neuritogenesis with a decreased expression of transthyretin, which is known to be downregulated by oxidative stress. Extracellular treatment with recombinant hTFAM effectively suppressed these deleterious outcomes. Moreover, the treatment increased expression of transthyretin, accompanied by reduction of intracellular Abeta. These results provide new insights into potential novel therapeutic targets. |
